Paliperidone extended-release in patients with non-acute schizophrenia previously unsuccessfully treated with other oral antipsychotics

Andreas Schreiner, Marjolein Lahaye, Joseph Peuskens, Dieter Naber, Nesrin Dilbaz, Bruno Millet, Manuel A. Franco, Elmars Rancans, Jacek Turczynski, Enrico Smeraldi, Elsa Lara, Nikolaj G. Neznanov

Research output: Contribution to journalArticle

Abstract

Objective: This study explores relevant outcomes with flexibly dosed paliperidone extended-release (ER) in a real-world design. Research design and methods: Patients were recruited from 23 countries. Adults with non-acute schizophrenia (n = 1812), previously unsuccessfully treated with other oral antipsychotics, were transitioned to paliperidone ER and prospectively treated for 6 months. Main outcome measures: Primary efficacy outcome for patients switching for the main reason of lack of efficacy was ≥ 20% improvement in Positive and Negative Syndrome Scale (PANSS) total scores. For patients switching for main reasons other than lack of efficacy, primary outcome was non-inferiority in efficacy compared with the previous medication. Results: Among the lack-of-efficacy group, 61% achieved a ≥ 20% improvement in PANSS total scores from baseline to endpoint. For switchers from other than the lack-of-efficacy group, efficacy maintenance after switching to paliperidone ER was confirmed. Clinically relevant and statistically significant symptomatic improvements occurred for each patient group based on main reason for switching. Conclusion: Paliperidone ER was well tolerated and associated with a meaningful clinical response in patients who switched from other oral antipsychotics, with insomnia and anxiety as most frequent side-effects.

Original languageEnglish
Pages (from-to)593-603
Number of pages11
JournalExpert Opinion on Pharmacotherapy
Volume15
Issue number5
DOIs
Publication statusPublished - 2014

Fingerprint

Antipsychotic Agents
Schizophrenia
Sleep Initiation and Maintenance Disorders
Research Design
Anxiety
Maintenance
Outcome Assessment (Health Care)
Paliperidone Palmitate

Keywords

  • Extended-release
  • Flexible dosing
  • Paliperidone
  • Schizophrenia
  • Switching

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Paliperidone extended-release in patients with non-acute schizophrenia previously unsuccessfully treated with other oral antipsychotics. / Schreiner, Andreas; Lahaye, Marjolein; Peuskens, Joseph; Naber, Dieter; Dilbaz, Nesrin; Millet, Bruno; Franco, Manuel A.; Rancans, Elmars; Turczynski, Jacek; Smeraldi, Enrico; Lara, Elsa; Neznanov, Nikolaj G.

In: Expert Opinion on Pharmacotherapy, Vol. 15, No. 5, 2014, p. 593-603.

Research output: Contribution to journalArticle

Schreiner, A, Lahaye, M, Peuskens, J, Naber, D, Dilbaz, N, Millet, B, Franco, MA, Rancans, E, Turczynski, J, Smeraldi, E, Lara, E & Neznanov, NG 2014, 'Paliperidone extended-release in patients with non-acute schizophrenia previously unsuccessfully treated with other oral antipsychotics', Expert Opinion on Pharmacotherapy, vol. 15, no. 5, pp. 593-603. https://doi.org/10.1517/14656566.2014.884071
Schreiner, Andreas ; Lahaye, Marjolein ; Peuskens, Joseph ; Naber, Dieter ; Dilbaz, Nesrin ; Millet, Bruno ; Franco, Manuel A. ; Rancans, Elmars ; Turczynski, Jacek ; Smeraldi, Enrico ; Lara, Elsa ; Neznanov, Nikolaj G. / Paliperidone extended-release in patients with non-acute schizophrenia previously unsuccessfully treated with other oral antipsychotics. In: Expert Opinion on Pharmacotherapy. 2014 ; Vol. 15, No. 5. pp. 593-603.
@article{72bdfb971feb45c088d6c32c5b4438c7,
title = "Paliperidone extended-release in patients with non-acute schizophrenia previously unsuccessfully treated with other oral antipsychotics",
abstract = "Objective: This study explores relevant outcomes with flexibly dosed paliperidone extended-release (ER) in a real-world design. Research design and methods: Patients were recruited from 23 countries. Adults with non-acute schizophrenia (n = 1812), previously unsuccessfully treated with other oral antipsychotics, were transitioned to paliperidone ER and prospectively treated for 6 months. Main outcome measures: Primary efficacy outcome for patients switching for the main reason of lack of efficacy was ≥ 20{\%} improvement in Positive and Negative Syndrome Scale (PANSS) total scores. For patients switching for main reasons other than lack of efficacy, primary outcome was non-inferiority in efficacy compared with the previous medication. Results: Among the lack-of-efficacy group, 61{\%} achieved a ≥ 20{\%} improvement in PANSS total scores from baseline to endpoint. For switchers from other than the lack-of-efficacy group, efficacy maintenance after switching to paliperidone ER was confirmed. Clinically relevant and statistically significant symptomatic improvements occurred for each patient group based on main reason for switching. Conclusion: Paliperidone ER was well tolerated and associated with a meaningful clinical response in patients who switched from other oral antipsychotics, with insomnia and anxiety as most frequent side-effects.",
keywords = "Extended-release, Flexible dosing, Paliperidone, Schizophrenia, Switching",
author = "Andreas Schreiner and Marjolein Lahaye and Joseph Peuskens and Dieter Naber and Nesrin Dilbaz and Bruno Millet and Franco, {Manuel A.} and Elmars Rancans and Jacek Turczynski and Enrico Smeraldi and Elsa Lara and Neznanov, {Nikolaj G.}",
year = "2014",
doi = "10.1517/14656566.2014.884071",
language = "English",
volume = "15",
pages = "593--603",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Taylor and Francis Ltd.",
number = "5",

}

TY - JOUR

T1 - Paliperidone extended-release in patients with non-acute schizophrenia previously unsuccessfully treated with other oral antipsychotics

AU - Schreiner, Andreas

AU - Lahaye, Marjolein

AU - Peuskens, Joseph

AU - Naber, Dieter

AU - Dilbaz, Nesrin

AU - Millet, Bruno

AU - Franco, Manuel A.

AU - Rancans, Elmars

AU - Turczynski, Jacek

AU - Smeraldi, Enrico

AU - Lara, Elsa

AU - Neznanov, Nikolaj G.

PY - 2014

Y1 - 2014

N2 - Objective: This study explores relevant outcomes with flexibly dosed paliperidone extended-release (ER) in a real-world design. Research design and methods: Patients were recruited from 23 countries. Adults with non-acute schizophrenia (n = 1812), previously unsuccessfully treated with other oral antipsychotics, were transitioned to paliperidone ER and prospectively treated for 6 months. Main outcome measures: Primary efficacy outcome for patients switching for the main reason of lack of efficacy was ≥ 20% improvement in Positive and Negative Syndrome Scale (PANSS) total scores. For patients switching for main reasons other than lack of efficacy, primary outcome was non-inferiority in efficacy compared with the previous medication. Results: Among the lack-of-efficacy group, 61% achieved a ≥ 20% improvement in PANSS total scores from baseline to endpoint. For switchers from other than the lack-of-efficacy group, efficacy maintenance after switching to paliperidone ER was confirmed. Clinically relevant and statistically significant symptomatic improvements occurred for each patient group based on main reason for switching. Conclusion: Paliperidone ER was well tolerated and associated with a meaningful clinical response in patients who switched from other oral antipsychotics, with insomnia and anxiety as most frequent side-effects.

AB - Objective: This study explores relevant outcomes with flexibly dosed paliperidone extended-release (ER) in a real-world design. Research design and methods: Patients were recruited from 23 countries. Adults with non-acute schizophrenia (n = 1812), previously unsuccessfully treated with other oral antipsychotics, were transitioned to paliperidone ER and prospectively treated for 6 months. Main outcome measures: Primary efficacy outcome for patients switching for the main reason of lack of efficacy was ≥ 20% improvement in Positive and Negative Syndrome Scale (PANSS) total scores. For patients switching for main reasons other than lack of efficacy, primary outcome was non-inferiority in efficacy compared with the previous medication. Results: Among the lack-of-efficacy group, 61% achieved a ≥ 20% improvement in PANSS total scores from baseline to endpoint. For switchers from other than the lack-of-efficacy group, efficacy maintenance after switching to paliperidone ER was confirmed. Clinically relevant and statistically significant symptomatic improvements occurred for each patient group based on main reason for switching. Conclusion: Paliperidone ER was well tolerated and associated with a meaningful clinical response in patients who switched from other oral antipsychotics, with insomnia and anxiety as most frequent side-effects.

KW - Extended-release

KW - Flexible dosing

KW - Paliperidone

KW - Schizophrenia

KW - Switching

UR - http://www.scopus.com/inward/record.url?scp=84896270088&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896270088&partnerID=8YFLogxK

U2 - 10.1517/14656566.2014.884071

DO - 10.1517/14656566.2014.884071

M3 - Article

C2 - 24491033

AN - SCOPUS:84896270088

VL - 15

SP - 593

EP - 603

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 5

ER -